https://scholars.lib.ntu.edu.tw/handle/123456789/580029
標題: | IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation | 作者: | Hack S.P. Spahn J. Chen M. ANN-LII CHENG Kaseb A. Kudo M. Lee H.C. Yopp A. Chow P. Qin S. |
關鍵字: | Ablation; Adjuvant treatment; Atezolizumab; Bevacizumab; Hepatocellular carcinoma; PD-L1; Recurrence-free survival; Resection; VEGF | 公開日期: | 2020 | 出版社: | Future Medicine Ltd. | 卷: | 16 | 期: | 15 | 起(迄)頁: | 975-989 | 來源出版物: | Future Oncology | 摘要: | Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT0410209. ? 2020 Stephen P. Hack. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084721342&doi=10.2217%2ffon-2020-0162&partnerID=40&md5=1e0b7a1488c42f38cb87ab21f0f39721 https://scholars.lib.ntu.edu.tw/handle/123456789/580029 |
ISSN: | 1479-6694 | DOI: | 10.2217/fon-2020-0162 | SDG/關鍵字: | atezolizumab; bevacizumab; antineoplastic agent; atezolizumab; bevacizumab; monoclonal antibody; ablation therapy; cancer recurrence; controlled study; high risk patient; human; liver cell carcinoma; liver resection; microwave thermotherapy; multicenter study; overall survival; phase 3 clinical trial; priority journal; progression free survival; radiofrequency ablation; randomized controlled trial; recurrence free survival; Review; study design; catheter ablation; clinical trial; female; liver cell carcinoma; liver resection; liver tumor; male; methodology; mortality; multimodality cancer therapy; postoperative care; retreatment; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Postoperative Care; Research Design; Retreatment |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。